Cargando…

Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis

Among people with multiple sclerosis, cognitive impairment occurs commonly and is a potent predictor of disability. Some multiple sclerosis patients present with severe cognitive impairment, and distinguishing multiple sclerosis-related cognitive impairment from co-existent progressive neurodegenera...

Descripción completa

Detalles Bibliográficos
Autores principales: Londoño, Diana P, Arumaithurai, Kogulavadanan, Constantopoulos, Eleni, Basso, Michael R, Reichard, R Ross, Flanagan, Eoin P, Keegan, B Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272064/
https://www.ncbi.nlm.nih.gov/pubmed/35822102
http://dx.doi.org/10.1093/braincomms/fcac167
_version_ 1784744813567934464
author Londoño, Diana P
Arumaithurai, Kogulavadanan
Constantopoulos, Eleni
Basso, Michael R
Reichard, R Ross
Flanagan, Eoin P
Keegan, B Mark
author_facet Londoño, Diana P
Arumaithurai, Kogulavadanan
Constantopoulos, Eleni
Basso, Michael R
Reichard, R Ross
Flanagan, Eoin P
Keegan, B Mark
author_sort Londoño, Diana P
collection PubMed
description Among people with multiple sclerosis, cognitive impairment occurs commonly and is a potent predictor of disability. Some multiple sclerosis patients present with severe cognitive impairment, and distinguishing multiple sclerosis-related cognitive impairment from co-existent progressive neurodegenerative diseases such as Alzheimer disease poses a diagnostic challenge. The use of biomarkers such as PET and CSF proteins may facilitate this distinction. The study was a retrospective, descriptive study on convenience samples of separate cohorts, one of cognitively impaired multiple sclerosis patients evaluated on autopsy to demonstrate coincidence of both multiple sclerosis and neurodegenerative cognitive diseases. The second cohort were cognitively impaired multiple sclerosis patients evaluated by biomarker to investigate possible additional neurodegenerative cognitive disorders contributing to the cognitive impairment. We investigated selected biomarkers among 31 severely impaired patients (biomarker cohort) and 12 severely impaired patients assessed at autopsy and selected 24 (23 biomarker cohort, 1 autopsy cohort) had comprehensive neurocognitive testing. Biomarker cohort investigations included 18F-Fluorodeoxyglucose PET and/or CSF amyloid Aβ1-42, phospho-tau and total tau levels. The autopsy cohort was evaluated with comprehensive neuropathological assessment for aetiology of cognitive impairment. The cohorts shared similar sex, age at multiple sclerosis onset and multiple sclerosis clinical course. The autopsy-cohort patients were older at diagnosis (69.5 versus 57 years, P = 0.006), had longer disease duration [median (range) 20 years (3–59) versus 9 (1–32), P = 0.001] and had more impaired bedside mental status scores at last follow-up [Kokmen median (range) 23 (1–38) versus 31 (9–34) P = 0.01]. Autopsy-cohort patients confirmed, or excluded, coexistent neurogenerative disease by neuropathology gold standard. Most biomarker-cohort patients had informative results evaluating coexistent neurogenerative disease. Biomarkers may be useful in indicating a coexistent neurodegenerative disease earlier, and in life, in patients with multiple sclerosis and significant cognitive impairment.
format Online
Article
Text
id pubmed-9272064
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92720642022-07-11 Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis Londoño, Diana P Arumaithurai, Kogulavadanan Constantopoulos, Eleni Basso, Michael R Reichard, R Ross Flanagan, Eoin P Keegan, B Mark Brain Commun Original Article Among people with multiple sclerosis, cognitive impairment occurs commonly and is a potent predictor of disability. Some multiple sclerosis patients present with severe cognitive impairment, and distinguishing multiple sclerosis-related cognitive impairment from co-existent progressive neurodegenerative diseases such as Alzheimer disease poses a diagnostic challenge. The use of biomarkers such as PET and CSF proteins may facilitate this distinction. The study was a retrospective, descriptive study on convenience samples of separate cohorts, one of cognitively impaired multiple sclerosis patients evaluated on autopsy to demonstrate coincidence of both multiple sclerosis and neurodegenerative cognitive diseases. The second cohort were cognitively impaired multiple sclerosis patients evaluated by biomarker to investigate possible additional neurodegenerative cognitive disorders contributing to the cognitive impairment. We investigated selected biomarkers among 31 severely impaired patients (biomarker cohort) and 12 severely impaired patients assessed at autopsy and selected 24 (23 biomarker cohort, 1 autopsy cohort) had comprehensive neurocognitive testing. Biomarker cohort investigations included 18F-Fluorodeoxyglucose PET and/or CSF amyloid Aβ1-42, phospho-tau and total tau levels. The autopsy cohort was evaluated with comprehensive neuropathological assessment for aetiology of cognitive impairment. The cohorts shared similar sex, age at multiple sclerosis onset and multiple sclerosis clinical course. The autopsy-cohort patients were older at diagnosis (69.5 versus 57 years, P = 0.006), had longer disease duration [median (range) 20 years (3–59) versus 9 (1–32), P = 0.001] and had more impaired bedside mental status scores at last follow-up [Kokmen median (range) 23 (1–38) versus 31 (9–34) P = 0.01]. Autopsy-cohort patients confirmed, or excluded, coexistent neurogenerative disease by neuropathology gold standard. Most biomarker-cohort patients had informative results evaluating coexistent neurogenerative disease. Biomarkers may be useful in indicating a coexistent neurodegenerative disease earlier, and in life, in patients with multiple sclerosis and significant cognitive impairment. Oxford University Press 2022-06-22 /pmc/articles/PMC9272064/ /pubmed/35822102 http://dx.doi.org/10.1093/braincomms/fcac167 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Londoño, Diana P
Arumaithurai, Kogulavadanan
Constantopoulos, Eleni
Basso, Michael R
Reichard, R Ross
Flanagan, Eoin P
Keegan, B Mark
Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis
title Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis
title_full Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis
title_fullStr Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis
title_full_unstemmed Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis
title_short Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis
title_sort diagnosis of coexistent neurodegenerative dementias in multiple sclerosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272064/
https://www.ncbi.nlm.nih.gov/pubmed/35822102
http://dx.doi.org/10.1093/braincomms/fcac167
work_keys_str_mv AT londonodianap diagnosisofcoexistentneurodegenerativedementiasinmultiplesclerosis
AT arumaithuraikogulavadanan diagnosisofcoexistentneurodegenerativedementiasinmultiplesclerosis
AT constantopouloseleni diagnosisofcoexistentneurodegenerativedementiasinmultiplesclerosis
AT bassomichaelr diagnosisofcoexistentneurodegenerativedementiasinmultiplesclerosis
AT reichardrross diagnosisofcoexistentneurodegenerativedementiasinmultiplesclerosis
AT flanaganeoinp diagnosisofcoexistentneurodegenerativedementiasinmultiplesclerosis
AT keeganbmark diagnosisofcoexistentneurodegenerativedementiasinmultiplesclerosis